Genpact Limited SEC Filings

Genpact Limited filed an automatic shelf registration (Form S-3) that allows it—and certain subsidiaries as co-issuers—to offer, from time to time after effectiveness, debt securities (with potential guarantees), common shares, preference shares, depositary shares, warrants, and units. Any specific terms and amounts will be set in future prospectus supplements. The company states it may sell directly, through agents, or via underwriters and dealers.

Net proceeds from any future primary offerings will be used for general corporate purposes, which may include acquisitions, debt repayment or refinancing, working capital, and capital expenditures. Genpact’s common shares trade on the NYSE under “G.” Shares outstanding were 172,414,423 as of November 3, 2025; this is a baseline figure, not the amount being offered.

G reported a Form 144 notice indicating a planned sale of up to 2,750 shares of common stock. The filing lists an aggregate market value of $125,537.50 and identifies Morgan Stanley Smith Barney LLC as the broker. The shares are expected to be sold on the NYSE with an approximate sale date of 11/12/2025.

The seller acquired 2,750 shares as restricted stock from the issuer on 12/31/2021 with “Not Applicable” listed for payment terms. Shares outstanding were 172,414,423; this is a baseline figure, not the amount being offered.

Form 144 filing reports a proposed sale of 4,351 common shares with an aggregate market value of $199,014.74. The approximate sale date is 11/12/2025, through Morgan Stanley Smith Barney LLC Executive Financial Services, with the shares listed on the NYSE.

The shares to be sold were acquired on 11/12/2025 via stock option exercise, with cash as the form of payment, in the same amount of 4,351 shares. The filing also discloses activity in the prior three months: Heather D White sold 1,039 shares on 11/11/2025 for $45,731.59.

This notice indicates intent to sell under Rule 144 and includes the required background on acquisition and recent sales.

Form 144 notice: A holder identified as Sameer Dewan filed to sell up to 26,531 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $1,185,999.37 and an approximate sale date of 11/11/2025 on the NYSE.

The shares were acquired from the issuer via equity awards: performance shares and restricted stock granted on 01/10/2021, 01/10/2022, and 01/10/2023, matching the proposed sale amount. Shares outstanding were 172,414,423. Over the past three months, the seller reported a prior sale of 20,078 shares on 08/28/2025 for gross proceeds of $903,510.

Genpact Limited reported higher quarterly results. Net revenues for Q3 2025 rose to $1,291,257 from $1,210,949 a year ago, with income from operations of $191,642. Net income increased to $145,831, and diluted EPS was $0.83 versus $0.74.

For the first nine months of 2025, net revenues reached $3,760,601 and net income was $409,400, with diluted EPS of $2.31. Operating cash flow strengthened to $526,161, supporting buybacks and dividends. Cash and cash equivalents were $740,763 as of September 30, 2025.

The company completed the acquisition of XponentL Data, Inc. for total consideration of $160,157, including $82,657 in cash at closing and an earn-out of $77,500. The deal added customer-related intangibles of $51,400 and goodwill of $112,271. Genpact repurchased 3,919,239 shares year-to-date for $182,905 and paid dividends totaling $88,701. Long-term debt (less current) declined to $827,046, while the current portion rose to $375,871, reflecting near-term maturities.

Genpact Limited furnished an update under Item 2.02, announcing it issued a press release with financial results for the three months ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.

The information, including Exhibit 99.1, is furnished—not filed—so it is not subject to Section 18 of the Exchange Act and will only be incorporated into other filings if expressly referenced. The company references non-GAAP measures in the release and provides reconciliations to comparable GAAP measures within Exhibit 99.1.

Genpact Ltd (G) reported an equity award to an officer. On 10/10/2025, the Chief Accounting Officer acquired 20,066 common shares at $0, reported as an award of unvested restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Following the transaction, beneficial ownership was 20,066 shares, held directly.

Each RSU converts into one common share upon vesting. The award vests in three equal installments on April 30, 2027, July 31, 2027, and October 31, 2027, subject to continued service through each vesting date.

Genpact LTD (G) filing an initial Form 3 shows Anthony J. Radesca, the company's Chief Accounting Officer and an officer-level reporting person, reported no beneficial ownership of Genpact securities.

The form lists the event date as 09/29/2025 and the filing was signed on 10/06/2025 by an attorney-in-fact. The filing includes an exhibit referencing a power of attorney and confirms this is an individual filing by one reporting person.

Genpact disclosed the appointment of Mr. Radesca as Senior Vice President and Chief Accounting Officer. The filing states he will receive a base salary, annual bonus opportunities, and equity awards appropriate to his role, and will be eligible for Company-sponsored benefits such as health, disability, and life insurance. The company disclosed there are no arrangements or understandings with other persons regarding his appointment, no family relationships with any director or executive officer, and no transactions in the last fiscal year (and none proposed) that would trigger related‑party disclosure under Regulation S-K Item 404(a).